Sex differences in pharmacokinetics of antidepressants

Bibliography

• Grigoriadis S, Robinson GE. Gender issues in depression. Ann Clin Psychiatry 2007;19(4):247-55
   PubMedGoogle Scholar
• Sloan DM, Kornstein SG. Gender differences in depression and response to antidepressant treatment. Psychiatr Clin North Am 2003;26(3):581-94
   PubMed Web of Science ®Google Scholar
• Frackiewicz EJ, Sramek JJ, Cutler NR. Gender differences in depression and antidepressant pharmacokinetics and adverse events. Ann Pharmacother 2000;34(1):80-8
   PubMed Web of Science ®Google Scholar
• Dalla C, Pitychoutis PM, Kokras N, Sex differences in animal models of depression and antidepressant response. Basic Clin Pharmacol Toxicol 2010;106(3):226-33
   PubMed Web of Science ®Google Scholar
• Dalla C, Antoniou K, Kokras N, Sex differences in the effects of two stress paradigms on dopaminergic neurotransmission. Physiol Behav 2008;93(3):595-605
   PubMed Web of Science ®Google Scholar
• Dalla C, Antoniou K, Drossopoulou G, Chronic mild stress impact: are females more vulnerable? Neuroscience 2005;135(3):703-14
   PubMed Web of Science ®Google Scholar
• Bigos KL, Pollock BG, Stankevich BA, Sex differences in the pharmacokinetics and pharmacodynamics of antidepressants: an updated review. Gend Med 2009;6(4):522-43
   PubMed Web of Science ®Google Scholar
• Bies RR, Bigos KL, Pollock BG. Gender differences in the pharmacokinetics and pharmacodynamics of antidepressants. J Gend Specif Med 2003;6(3):12-20
   PubMedGoogle Scholar
• Kornstein SG, McEnany G. Enhancing pharmacologic effects in the treatment of depression in women. J Clin Psychiatry 2000;61(Suppl 11):18-27
   PubMedGoogle Scholar
• Yonkers KA, Brawman-Mintzer O. The pharmacologic treatment of depression: is gender a critical factor? J Clin Psychiatry 2002;63(7):610-15
   PubMed Web of Science ®Google Scholar
• Kokras N, Antoniou K, Polissidis A, Antidepressants induce regionally discrete, sex-dependent changes in brain's glutamate content. Neurosci Lett 2009;464(2):98-102
   PubMed Web of Science ®Google Scholar
• Pitychoutis PM, Griva E, Ioannou K, Chronic antidepressant treatment exerts sexually dimorphic immunomodulatory effects in an experimental model of major depression: do females lack an advantage? Int J Neuropsychopharmacol 2009;12(9):1157-63
   PubMed Web of Science ®Google Scholar
• Kokras N, Antoniou K, Dalla C, Sex-related differential response to clomipramine treatment in a rat model of depression. J Psychopharmacol 2009;23(8):945-56
   PubMed Web of Science ®Google Scholar
• Harris RZ, Benet LZ, Schwartz JB. Gender effects in pharmacokinetics and pharmacodynamics. Drugs 1995;50(2):222-39
   PubMed Web of Science ®Google Scholar
• Gleiter CH, Gundert-Remy U. Gender differences in pharmacokinetics. Eur J Drug Metab Pharmacokinet 1996;21(2):123-8
   PubMed Web of Science ®Google Scholar
• Anderson GD. Sex and racial differences in pharmacological response: where is the evidence? Pharmacogenetics, pharmacokinetics, and pharmacodynamics. J Womens Health 2005;14(1):19-29
   PubMed Web of Science ®Google Scholar
• Dawkins K, Potter WZ. Gender differences in pharmacokinetics and pharmacodynamics of psychotropics: focus on women. Psychopharmacol Bull 1991;27(4):417-26
   PubMed Web of Science ®Google Scholar
• Preskorn SH, Fast GA. Therapeutic drug monitoring for antidepressants: efficacy, safety, and cost effectiveness. J Clin Psychiatry 1991;52(Suppl):23-33
   PubMedGoogle Scholar
• Rasmussen BB, Brosen K. Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors? Ther Drug Monit 2000;22(2):143-54
   PubMed Web of Science ®Google Scholar
• Vaswani M, Linda FK, Ramesh S. Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review. Prog Neuropsychopharmacol Biol Psychiatry 2003;27(1):85-102
   PubMed Web of Science ®Google Scholar
• Amsterdam JD, Fawcett J, Quitkin FM, Fluoxetine and norfluoxetine plasma concentrations in major depression: a multicenter study. Am J Psychiatry 1997;154(7):963-9
   PubMed Web of Science ®Google Scholar
• Schnoll RA, Patterson F. Sex heterogeneity in pharmacogenetic smoking cessation clinical trials. Drug Alcohol Depend 2009;104(Suppl 1):S94-9
   PubMedGoogle Scholar
• Anderson GD. Gender differences in pharmacological response. Int Rev Neurobiol 2008;83:1-10
   PubMed Web of Science ®Google Scholar
• Schwartz JB. The influence of sex on pharmacokinetics. Clin Pharmacokinet 2003;42(2):107-21
   PubMed Web of Science ®Google Scholar
• Meibohm B, Beierle I, Derendorf H. How important are gender differences in pharmacokinetics? Clin Pharmacokinet 2002;41(5):329-42
   PubMed Web of Science ®Google Scholar
• Thompson DS, Pollock BG. Psychotropic metabolism: gender-related issues. Psychiatr Times 2001;18:46-8
   Google Scholar
• Yonkers KA, Wisner KL, Stewart DE, The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. Gen Hosp Psychiatry 2009;31(5):403-13
   PubMed Web of Science ®Google Scholar
• Udechuku A, Nguyen T, Hill R, Antidepressants in pregnancy: a systematic review. Aust N Z J Psychiatry 2010;44(11):978-96
   PubMed Web of Science ®Google Scholar
• Kashuba AD, Nafziger AN, Kearns GL, Quantification of intraindividual variability and the influence of menstrual cycle phase on CYP2D6 activity as measured by dextromethorphan phenotyping. Pharmacogenetics 1998;8(5):403-10
   PubMedGoogle Scholar
• Bennett EJ, Evans P, Scott AM, Psychological and sex features of delayed gut transit in functional gastrointestinal disorders. Gut 2000;46(1):83-7
   PubMed Web of Science ®Google Scholar
• Nicolas JM, Espie P, Molimard M. Gender and interindividual variability in pharmacokinetics. Drug Metab Rev 2009;41(3):408-21
   PubMed Web of Science ®Google Scholar
• Kristensen CB. Imipramine serum protein binding in healthy subjects. Clin Pharmacol Ther 1983;34(5):689-94
   PubMed Web of Science ®Google Scholar
• Kashuba AD, Nafziger AN. Physiological changes during the menstrual cycle and their effects on the pharmacokinetics and pharmacodynamics of drugs. Clin Pharmacokinet 1998;34(3):203-18
   PubMed Web of Science ®Google Scholar
• Nicolson TJ, Mellor HR, Roberts RR. Gender differences in drug toxicity. Trends Pharmacol Sci 2010;31(3):108-14
   PubMed Web of Science ®Google Scholar
• Waxman DJ, Holloway MG. Sex differences in the expression of hepatic drug metabolizing enzymes. Mol Pharmacol 2009;76(2):215-28
   PubMed Web of Science ®Google Scholar
• Pitychoutis PM, Zisaki A, Dalla C, Pharmacogenetic insights into depression and antidepressant response: does sex matter? Curr Pharm Des 2010;16(20):2214-23
   PubMed Web of Science ®Google Scholar
• Veldhuis JD, Bowers CY. Human GH pulsatility: an ensemble property regulated by age and gender. J Endocrinol Invest 2003;26(9):799-813
   PubMed Web of Science ®Google Scholar
• Martin G, Gan TJ. Gender difference: hype or fact? Semin Anesth Perioperat Med Pain 2000;19(2):76-82
   Google Scholar
• Sinues B, Fanlo A, Mayayo E, CYP2A6 activity in a healthy Spanish population: effect of age, sex, smoking, and oral contraceptives. Hum Exp Toxicol 2008;27(5):367-72
   PubMed Web of Science ®Google Scholar
• Higashi E, Fukami T, Itoh M, Human CYP2A6 is induced by estrogen via estrogen receptor. Drug Metab Dispos 2007;35(10):1935-41
   PubMed Web of Science ®Google Scholar
• Lamba V, Lamba J, Yasuda K, Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression. J Pharmacol Exp Ther 2003;307(3):906-22
   PubMed Web of Science ®Google Scholar
• Schwartz JB. The current state of knowledge on age, sex, and their interactions on clinical pharmacology. Clin Pharmacol Ther 2007;82(1):87-96
   PubMed Web of Science ®Google Scholar
• Tamminga WJ, Wemer J, Oosterhuis B, CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers: indications for oral contraceptive-related gender differences. Eur J Clin Pharmacol 1999;55(3):177-84
   PubMed Web of Science ®Google Scholar
• Franconi F, Brunelleschi S, Steardo L, Gender differences in drug responses. Pharmacol Res 2007;55(2):81-95
   PubMed Web of Science ®Google Scholar
• Court MH, Hao Q, Krishnaswamy S, UDP-glucuronosyltransferase (UGT) 2B15 pharmacogenetics: UGT2B15 D85Y genotype and gender are major determinants of oxazepam glucuronidation by human liver. J Pharmacol Exp Ther 2004;310(2):656-65
   PubMed Web of Science ®Google Scholar
• Physicians Desk Reference. Physicians' Desk Reference. 63rd edition. Thomson PDR, Montvale, NJ; 2009
   Google Scholar
• Leinonen E, Lepola U, Koponen H, The effect of age and concomitant treatment with other psychoactive drugs on serum concentrations of citalopram measured with a nonenantioselective method. Ther Drug Monit 1996;18(2):111-17
   PubMed Web of Science ®Google Scholar
• Bezchlibnyk-Butler K, Aleksic I, Kennedy SH. Citalopram – a review of pharmacological and clinical effects. J Psychiatry Neurosci 2000;25(3):241-54
   PubMed Web of Science ®Google Scholar
• Fudio S, Borobia AM, Pinana E, Evaluation of the influence of sex and CYP2C19 and CYP2D6 polymorphisms in the disposition of citalopram. Eur J Pharmacol 2010;626(2-3):200-4
   PubMed Web of Science ®Google Scholar
• Jin Y, Pollock BG, Frank E, Effect of age, weight, and CYP2C19 genotype on escitalopram exposure. J Clin Pharmacol 2010;50(1):62-72
   PubMed Web of Science ®Google Scholar
• de Mendonca Lima CA, Baumann P, Brawand-Amey M, Effect of age and gender on citalopram and desmethylcitalopram steady-state plasma concentrations in adults and elderly depressed patients. Prog Neuropsychopharmacol Biol Psychiatry 2005;29(6):952-6
   PubMedGoogle Scholar
• Bies RR, Feng Y, Lotrich FE, Utility of sparse concentration sampling for citalopram in elderly clinical trial subjects. J Clin Pharmacol 2004;44(12):1352-9
   PubMed Web of Science ®Google Scholar
• Le Bloc'h Y, Woggon B, Weissenrieder H, Routine therapeutic drug monitoring in patients treated with 10-360 mg/day citalopram. Ther Drug Monit 2003;25(5):600-8
   PubMed Web of Science ®Google Scholar
• Reis M, Lundmark J, Bengtsson F. Therapeutic drug monitoring of racemic citalopram: a 5-year experience in Sweden, 1992-1997. Ther Drug Monit 2003;25(2):183-91
   PubMed Web of Science ®Google Scholar
• Reis M, Olsson G, Carlsson B, Serum levels of citalopram and its main metabolites in adolescent patients treated in a naturalistic clinical setting. J Clin Psychopharmacol 2002;22(4):406-13
   PubMed Web of Science ®Google Scholar
• Reis M, Cherma MD, Carlsson B, Therapeutic drug monitoring of escitalopram in an outpatient setting. Ther Drug Monit 2007;29(6):758-66
   PubMed Web of Science ®Google Scholar
• Reis M, Aamo T, Spigset O, Serum concentrations of antidepressant drugs in a naturalistic setting: compilation based on a large therapeutic drug monitoring database. Ther Drug Monit 2009;31(1):42-56
   PubMed Web of Science ®Google Scholar
• Hodes GE, Hill-Smith TE, Suckow RF, Sex-specific effects of chronic fluoxetine treatment on neuroplasticity and pharmacokinetics in mice. J Pharmacol Exp Ther 2010;332(1):266-73
   PubMed Web of Science ®Google Scholar
• Ferguson JM, Hill H. Pharmacokinetics of fluoxetine in elderly men and women. Gerontology 2006;52(1):45-50
   PubMed Web of Science ®Google Scholar
• Jannuzzi G, Gatti G, Magni P, Plasma concentrations of the enantiomers of fluoxetine and norfluoxetine: sources of variability and preliminary observations on relations with clinical response. Ther Drug Monit 2002;24(5):616-27
   PubMed Web of Science ®Google Scholar
• Preskorn SH. Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Clin Pharmacokinet 1997;32(Suppl 1):1-21
   PubMedGoogle Scholar
• Hartter S, Wetzel H, Hammes E, Nonlinear pharmacokinetics of fluvoxamine and gender differences. Ther Drug Monit 1998;20(4):446-9
   PubMed Web of Science ®Google Scholar
• van den Broek WW, Birkenhager TK, Mulder PG, Time-dependent clearance decrements of fluvoxamine in depressed inpatients: a clinical evaluation. J Clin Psychopharmacol 2007;27(2):231-3
   PubMed Web of Science ®Google Scholar
• Findling RL, Nucci G, Piergies AA, Multiple dose pharmacokinetics of paroxetine in children and adolescents with major depressive disorder or obsessive-compulsive disorder. Neuropsychopharmacology 2006;31(6):1274-85
   PubMed Web of Science ®Google Scholar
• Sawamura K, Suzuki Y, Someya T. Effects of dosage and CYP2D6-mutated allele on plasma concentration of paroxetine. Eur J Clin Pharmacol 2004;60(8):553-7
   PubMed Web of Science ®Google Scholar
• Feng Y, Pollock BG, Ferrell RE, Paroxetine: population pharmacokinetic analysis in late-life depression using sparse concentration sampling. Br J Clin Pharmacol 2006;61(5):558-69
   PubMed Web of Science ®Google Scholar
• Reis M, Aberg-Wistedt A, Agren H, Serum disposition of sertraline, N-desmethylsertraline and paroxetine: a pharmacokinetic evaluation of repeated drug concentration measurements during 6 months of treatment for major depression. Hum Psychopharmacol 2004;19(5):283-91
   PubMed Web of Science ®Google Scholar
• Gex-Fabry M, Eap CB, Oneda B, CYP2D6 and ABCB1 genetic variability: influence on paroxetine plasma level and therapeutic response. Ther Drug Monit 2008;30(4):474-82
   PubMed Web of Science ®Google Scholar
• Alderman J, Wolkow R, Fogel IM. Drug concentration monitoring with tolerability and efficacy assessments during open-label, long-term sertraline treatment of children and adolescents. J Child Adolesc Psychopharmacol 2006;16(1-2):117-29
   PubMed Web of Science ®Google Scholar
• Almeida S, Portoles A, Terleira A, Comparative bioavailability/bioequivalence of two different sertraline formulations: a randomised, 2-period × 2-sequence, crossover clinical trial in healthy volunteers. Arzneimittelforschung 2005;55(4):191-7
   PubMed Web of Science ®Google Scholar
• Ronfeld RA, Tremaine LM, Wilner KD. Pharmacokinetics of sertraline and its N-demethyl metabolite in elderly and young male and female volunteers. Clin Pharmacokinetics 1997;32(Suppl 1):22-30
   PubMedGoogle Scholar
• Jannuzzo MG, Ryde M, Karlmark B, P-2-77 pharmacokinetics of reboxetine in healthy volunteers of different ages. Eur Neuropsychopharmacol 1995;5(3):300
   Google Scholar
• Fleishaker JC, Mucci M, Pellizzoni C, Absolute bioavailability of reboxetine enantiomers and effect of gender on pharmacokinetics. Biopharm Drug Dispos 1999;20(1):53-7
   PubMed Web of Science ®Google Scholar
• Ohman D, Cherma MD, Norlander B, Determination of serum reboxetine enantiomers in patients on chronic medication with racemic reboxetine. Ther Drug Monit 2003;25(2):174-82
   PubMed Web of Science ®Google Scholar
• Lobo ED, Quinlan T, O'Brien L, Population pharmacokinetics of orally administered duloxetine in patients: implications for dosing recommendation. Clin Pharmacokinet 2009;48(3):189-97
   PubMed Web of Science ®Google Scholar
• Klamerus KJ, Parker VD, Rudolph RL, Effects of age and gender on venlafaxine and O-desmethylvenlafaxine pharmacokinetics. Pharmacotherapy 1996;16(5):915-23
   PubMed Web of Science ®Google Scholar
• Gex-Fabry M, Rudaz S, Balant-Gorgia AE, Steady-state concentration of venlafaxine enantiomers: model-based analysis of between-patient variability. Eur J Clin Pharmacol 2002;58(5):323-31
   PubMed Web of Science ®Google Scholar
• Reis M, Lundmark J, Bjork H, Therapeutic drug monitoring of racemic venlafaxine and its main metabolites in an everyday clinical setting. Ther Drug Monit 2002;24(4):545-53
   PubMed Web of Science ®Google Scholar
• Stewart JJ, Berkel HJ, Parish RC, Single-dose pharmacokinetics of bupropion in adolescents: effects of smoking status and gender. J Clin Pharmacol 2001;41(7):770-8
   PubMed Web of Science ®Google Scholar
• Daviss WB, Perel JM, Rudolph GR, Steady-state pharmacokinetics of bupropion SR in juvenile patients. J Am Acad Child Adolesc Psychiatry 2005;44(4):349-57
   PubMed Web of Science ®Google Scholar
• Findlay JW, Van Wyck Fleet J, Smith PG, Pharmacokinetics of bupropion, a novel antidepressant agent, following oral administration to healthy subjects. Eur J Clin Pharmacol 1981;21(2):127-35
   PubMed Web of Science ®Google Scholar
• Hsyu PH, Singh A, Giargiari TD, Pharmacokinetics of bupropion and its metabolites in cigarette smokers versus nonsmokers. J Clin Pharmacol 1997;37(8):737-43
   PubMed Web of Science ®Google Scholar
• Sweet RA, Pollock BG, Kirshner M, Pharmacokinetics of single- and multiple-dose bupropion in elderly patients with depression. J Clin Pharmacol 1995;35(9):876-84
   PubMed Web of Science ®Google Scholar
• Burrows G, Scoggins BA, Turecek LR, Plasma nortriptyline and clinical response. Clin Pharmacol Ther 1974;16(4):639-44
   PubMed Web of Science ®Google Scholar
• Ziegler VE, Biggs JT. Tricyclic plasma levels. Effect of age, race, sex, and smoking. JAMA 1977;238(20):2167-9
   PubMed Web of Science ®Google Scholar
• Masubuchi Y, Iwasa T, Fujita S, Regioselectivity and substrate concentration-dependency of involvement of the CYP2D subfamily in oxidative metabolism of amitriptyline and nortriptyline in rat liver microsomes. J Pharm Pharmacol 1996;48(9):925-9
   PubMed Web of Science ®Google Scholar
• Preskorn SH, Mac DS. Plasma levels of amitriptyline: effect of age and sex. J Clin Psychiatry 1985;46(7):276-7
   PubMed Web of Science ®Google Scholar
• Hammer W, Sjoqvist F. Plasma levels of monomethylated tricyclic antidepressants during treatment with imipramine-like compounds. Life Sci 1967;6(17):1895-903
   PubMedGoogle Scholar
• Dawling S. Monitoring of tricyclic antidepressant therapy. Clin Biochem 1982;15(1):56-61
   PubMed Web of Science ®Google Scholar
• Dawling S, Crome P, Braithwaite R. Pharmacokinetics of single oral doses of nortriptyline in depressed elderly hospital patients and young healthy volunteers. Clin Pharmacokinet 1980;5(4):394-401
   PubMed Web of Science ®Google Scholar
• Dahl ML, Bertilsson L, Nordin C. Steady-state plasma levels of nortriptyline and its 10-hydroxy metabolite: relationship to the CYP2D6 genotype. Psychopharmacology (Berl) 1996;123(4):315-9
   PubMed Web of Science ®Google Scholar
• Nordin C. CSF/plasma ratio of 10-hydroxynortriptyline is influenced by sex and body height. Psychopharmacology (Berl) 1993;113(2):222-4
   PubMed Web of Science ®Google Scholar
• Jerling M, Merle Y, Mentre F, Population pharmacokinetics of nortriptyline during monotherapy and during concomitant treatment with drugs that inhibit CYP2D6 – an evaluation with the nonparametric maximum likelihood method. Br J Clin Pharmacol 1994;38(5):453-62
   PubMed Web of Science ®Google Scholar
• Schmider J, Deuschle M, Schweiger U, Amitriptyline metabolism in elderly depressed patients and normal controls in relation to hypothalamic-pituitary-adrenal system function. J Clin Psychopharmacol 1995;15(4):250-8
   PubMed Web of Science ®Google Scholar
• King JN, Maurer MP, Altmann BO, Pharmacokinetics of clomipramine in dogs following single-dose and repeated-dose oral administration. Am J Vet Res 2000;61(1):80-5
   PubMed Web of Science ®Google Scholar
• Lainesse C, Frank D, Beaudry F, Comparative oxidative metabolic profiles of clomipramine in cats, rats and dogs: preliminary results from an in vitro study. J Vet Pharmacol Ther 2007;30(5):387-93
   PubMed Web of Science ®Google Scholar
• Lainesse C, Frank D, Beaudry F, Effects of physiological covariables on pharmacokinetic parameters of clomipramine in a large population of cats after a single oral administration. J Vet Pharmacol Ther 2007;30(2):116-26
   PubMed Web of Science ®Google Scholar
• Shimoda K, Jerling M, Bottiger Y, Pronounced differences in the dispositon of clomipramine between Japanese and Swedish patients. J Clin Psychopharmacol 1999;19(5):393-400
   PubMed Web of Science ®Google Scholar
• Mundo E, Bareggi SR, Pirola R, Effect of acute intravenous clomipramine and antiobsessional response to proserotonergic drugs: is gender a predictive variable? Biol Psychiatry 1999;45(3):290-4
   PubMed Web of Science ®Google Scholar
• Mundo E, Pirola R, Bellodi L, Are gender differences in antiobsessional response related to different clomipramine metabolism? J Clin Psychopharmacol 2002;22(3):341-2
   PubMed Web of Science ®Google Scholar
• Hildebrandt MG, Steyerberg EW, Stage KB, Are gender differences important for the clinical effects of antidepressants? Am J Psychiatry 2003;160(9):1643-50
   PubMed Web of Science ®Google Scholar
• Gex-Fabry M, Balant-Gorgia AE, Balant LP, Clomipramine metabolism. Model-based analysis of variability factors from drug monitoring data. Clin Pharmacokinetics 1990;19(3):241-55
   PubMed Web of Science ®Google Scholar
• Biegon A, Samuel D. The in vivo distribution of an antidepressant drug (DMI) in male and female rats. Psychopharmacology (Berl) 1979;65(3):259-63
   PubMed Web of Science ®Google Scholar
• Wilson MA, Roy EJ. Pharmacokinetics of imipramine are affected by age and sex in rats. Life Sci 1986;38(8):711-18
   PubMed Web of Science ®Google Scholar
• Pscheidt GR. Demethylation of imipramine in male and female rats. Biochem Pharmacol 1962;1:501-2
   PubMedGoogle Scholar
• Nagy A, Treiber L. Quantitative determination of imipramine and desipramine in human blood plasma by direct densitometry of thin-layer chromatograms. J Pharm Pharmacol 1973;25(8):599-603
   PubMed Web of Science ®Google Scholar
• Masubuchi Y, Igarashi S, Suzuki T, Imipramine-induced inactivation of a cytochrome P450 2D enzyme in rat liver microsomes: in relation to covalent binding of its reactive intermediate. J Pharmacol Exp Ther 1996;279(2):724-31
   PubMed Web of Science ®Google Scholar
• Chiba M, Nishihara E, Fujita S, Position selective sex difference in imipramine metabolism in rat liver microsomes. Biochem Pharmacol 1985;34(6):898-900
   PubMed Web of Science ®Google Scholar
• Fujita S, Morimoto R, Chiba M, Evaluation of the involvement of a male specific cytochrome P-450 isozyme in senescence-associated decline of hepatic drug metabolism in male rats. Biochem Pharmacol 1989;38(22):3925-31
   PubMed Web of Science ®Google Scholar
• Cohen LG, Biederman J, Wilens TE, Desipramine clearance in children and adolescents: absence of effect of development and gender. J Am Acad Child Adolesc Psychiatry 1999;38(1):79-85
   PubMed Web of Science ®Google Scholar
• Abernethy DR, Greenblatt DJ, Shader RI. Imipramine and desipramine disposition in the elderly. J Pharmacol Exp Ther 1985;232(1):183-8
   PubMed Web of Science ®Google Scholar
• Moody JP, Tait AC, Todrick A. Plasma levels of imipramine and desmethylimipramine during therapy. Br J Psychiatry 1967;113(495):183-93
   PubMed Web of Science ®Google Scholar
• Abernethy DR, Greenblatt DJ, Shader RI. Imipramine disposition in users of oral contraceptive steroids. Clin Pharmacol Ther 1984;35(6):792-7
   PubMed Web of Science ®Google Scholar
• Maguire KP, Norman TR, McIntyre I, Clinical pharmacokinetics of dothiepin. Single-dose kinetics in patients and prediction of steady-state concentrations. Clin Pharmacokinet 1983;8(2):179-85
   PubMed Web of Science ®Google Scholar
• Masubuchi Y, Konishi M, Horie T. Imipramine- and mianserin-induced acute cell injury in primary cultured rat hepatocytes: implication of different cytochrome P450 enzymes. Arch Toxicol 1999;73(3):147-51
   PubMed Web of Science ®Google Scholar
• Reis M, Prochazka J, Sitsen A, Inter- and intraindividual pharmacokinetic variations of mirtazapine and its N-demethyl metabolite in patients treated for major depressive disorder: a 6-month therapeutic drug monitoring study. Ther Drug Monit 2005;27(4):469-77
   PubMed Web of Science ®Google Scholar
• Timmer CJ, Paanakker JE, Van Hal HJM. Pharmacokinetics of mirtazapine from orally administered tablets: influence of gender, age and treatment regimen. Hum Psychopharmacol 1996;11(6):497-509
   Web of Science ®Google Scholar
• Fawcett J, Barkin RL. Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression. J Affect Disord 1998;51(3):267-85
   PubMed Web of Science ®Google Scholar
• Borobia AM, Novalbos J, Guerra-Lopez P, Influence of sex and CYP2D6 genotype on mirtazapine disposition, evaluated in Spanish healthy volunteers. Pharmacol Res 2009;59(6):393-8
   PubMed Web of Science ®Google Scholar
• Barbhaiya RH, Shukla UA, Greene DS. Single-dose pharmacokinetics of nefazodone in healthy young and elderly subjects and in subjects with renal or hepatic impairment. Eur J Clin Pharmacol 1995;49(3):221-8
   PubMed Web of Science ®Google Scholar
• Barbhaiya RH, Buch AB, Greene DS. A study of the effect of age and gender on the pharmacokinetics of nefazodone after single and multiple doses. J Clin Psychopharmacol 1996;16(1):19-25
   PubMed Web of Science ®Google Scholar
• Greene DS, Barbhaiya RH. Clinical pharmacokinetics of nefazodone. Clin Pharmacokinet 1997;33(4):260-75
   PubMed Web of Science ®Google Scholar
• Ishida M, Otani K, Kaneko S, Effects of various factors on steady state plasma concentrations of trazodone and its active metabolite m-chlorophenylpiperazine. Int Clin Psychopharmacol 1995;10(3):143-6
   PubMed Web of Science ®Google Scholar
• Prapotnik M, Waschgler R, Konig P, Therapeutic drug monitoring of trazodone: are there pharmacokinetic interactions involving citalopram and fluoxetine? Int J Clin Pharmacol Ther 2004;42(2):120-4
   PubMed Web of Science ®Google Scholar
• Greenblatt DJ, Friedman H, Burstein ES, Trazodone kinetics: effect of age, gender, and obesity. Clin Pharmacol Ther 1987;42(2):193-200
   PubMed Web of Science ®Google Scholar
• Gex-Fabry M, Balant-Gorgia AE, Balant LP. Potential of concentration monitoring data for a short half-life drug: analysis of pharmacokinetic variability for moclobemide. Ther Drug Monit 1995;17(1):39-46
   PubMed Web of Science ®Google Scholar
• Pfuhlmann B, Gerlach M, Burger R, Therapeutic drug monitoring of tricyclic antidepressants in everyday clinical practice. J Neural Transm Suppl 2007;(72):287-96
   PubMed Web of Science ®Google Scholar
• Beierle I, Meibohm B, Derendorf H. Gender differences in pharmacokinetics and pharmacodynamics. Int J Clin Pharmacol Ther 1999;37(11):529-47
   PubMed Web of Science ®Google Scholar
• Tsai SJ, Gau YT, Hong CJ, Sexually dimorphic effect of catechol-O-methyltransferase val158met polymorphism on clinical response to fluoxetine in major depressive patients. J Affect Disord 2009;113(1-2):183-7
   PubMed Web of Science ®Google Scholar
• Kornstein SG, Clayton AH, Soares CN, Analysis by age and sex of efficacy data from placebo-controlled trials of desvenlafaxine in outpatients with major depressive disorder. J Clin Psychopharmacol 2010;30(3):294-9
   PubMed Web of Science ®Google Scholar